These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1687848)

  • 21. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current practices in preclinical drug development: gaps in hemostasis testing to assess risk of thromboembolic injury.
    Schultze AE; Walker DB; Turk JR; Tarrant JM; Brooks MB; Pettit SD
    Toxicol Pathol; 2013; 41(3):445-53. PubMed ID: 22991386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabonomics in the preclinical and environmental toxicity field.
    Colet JM
    Drug Discov Today Technol; 2015 Jun; 13():3-10. PubMed ID: 26190677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of documentation requirements for preclinical sections, for marketing submissions in the European Community, Japan and the USA.
    Marr AP; Scales MD
    Adverse Drug React Toxicol Rev; 1993; 12(4):253-62. PubMed ID: 8142578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JALA special issue: microengineered cell- and tissue-based assays for drug screening and toxicology applications.
    Huh DD; Kim DH
    J Lab Autom; 2015 Apr; 20(2):79-81. PubMed ID: 25795434
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunotoxicant screening and prioritization in the twenty-first century.
    Luebke R
    Toxicol Pathol; 2012; 40(2):294-9. PubMed ID: 22105646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of hematologic parameters in applying the principles of toxicity testing to biotechnology products.
    Payne BJ
    Prog Clin Biol Res; 1987; 235():107-20. PubMed ID: 3601999
    [No Abstract]   [Full Text] [Related]  

  • 29. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The principles and practice of toxigenomics: applications and opportunities.
    Pennie WD; Tugwood JD; Oliver GJ; Kimber I
    Toxicol Sci; 2000 Apr; 54(2):277-83. PubMed ID: 10774809
    [No Abstract]   [Full Text] [Related]  

  • 31. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug safety and therapeutic index / Principles of pharmacological screening and of the clinical transferability of animal experiments results (author's transl)].
    Schneider B
    Arzneimittelforschung; 1982; 32(5):471-4. PubMed ID: 7201820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Basic in-vitro toxicity testing on cell cultures].
    Ioniţă I
    Bacteriol Virusol Parazitol Epidemiol; 1995; 40(3-4):181-5. PubMed ID: 8639991
    [No Abstract]   [Full Text] [Related]  

  • 35. Biopharmaceutical studies, a key to better toxicology.
    Zbinden G
    Xenobiotica; 1988 Jan; 18 Suppl 1():9-14. PubMed ID: 3344592
    [No Abstract]   [Full Text] [Related]  

  • 36. Pitfalls in forensic toxicology.
    Richardson T
    Ann Clin Biochem; 2000 Jan; 37 ( Pt 1)():20-44. PubMed ID: 10672370
    [No Abstract]   [Full Text] [Related]  

  • 37. Innovation in safety pharmacology testing.
    Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Embracing complexity in drug discovery.
    Gund P; Maliski E; Brown F
    Curr Opin Drug Discov Devel; 2007 May; 10(3):252-3. PubMed ID: 17554850
    [No Abstract]   [Full Text] [Related]  

  • 39. Toxicity testing, hazard assessment and data quality assurance for chemical regulatory purposes.
    Noel PR
    Dev Toxicol Environ Sci; 1980; 8():453-63. PubMed ID: 7308045
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug discrimination in behavioral toxicology.
    Colpaert FC
    Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med; 1987 Oct; 185(1-2):48-51. PubMed ID: 3124387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.